+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Jublia"

From
From
From
From
Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028 - Product Thumbnail Image

Dermatophytic Onychomycosis: US Drug Forecast and Market Analysis to 2028

  • Report
  • January 2020
  • 76 Pages
  • United States
From
Jublia - API Insight, 2022 - Product Thumbnail Image

Jublia - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Jublia- Drug Insight, 2019 - Product Thumbnail Image

Jublia- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
Onychomycosis Market Report and Forecast 2024-2032 - Product Thumbnail Image

Onychomycosis Market Report and Forecast 2024-2032

  • Report
  • October 2023
  • 160 Pages
  • Global
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Jublia is a brand of antifungal medication used to treat fungal infections of the toenails. It is a topical solution that is applied directly to the affected area. The active ingredient in Jublia is efinaconazole, which is a triazole antifungal. It works by inhibiting the growth of the fungus and preventing it from spreading. Jublia is used to treat onychomycosis, which is a fungal infection of the toenails. It is also used to prevent the recurrence of the infection. Jublia is part of the larger market of infectious diseases drugs, which are medications used to treat a variety of infections caused by bacteria, viruses, fungi, and parasites. These drugs are used to treat a wide range of conditions, from the common cold to more serious illnesses such as HIV/AIDS and malaria. Some companies in the Jublia market include Novartis, Merck, Pfizer, and GlaxoSmithKline. These companies are all major players in the pharmaceutical industry and have a wide range of products in the infectious diseases drugs market. Show Less Read more